Scipher Medicine
Contact
Search
Platform
Solutions
Company
Latest
Careers
Contact
Join Us
All articles
All articles
Press Releases
Publications
News Articles
Media Kit
Show all
Press Releases
Publications
News Articles
Media Kit
1/10/23
Press releases
Scipher Medicine Acquires CrossBridge and its SaaS Platform to Collect and Map Patient Molecular, Outcomes and Claims Data in Real Time
11/10/22
Press releases
Scipher Medicine Announces Publication of Positive Results From AIMS Clinical Study
11/4/22
Publications
Patient outcomes improve when a molecular signature test guides treatment decision-making in rheumatoid arthritis
6/1/22
Publications
Evaluation of physician global assessment in patients with b/tsDMARD therapy selection aligned with a molecular signature response classifier: an analysis from The Study to Accelerate Information of Molecular Signatures (AIMS) in Rheumatoid Arthritis
5/24/22
Press releases
Galapagos In-licenses Novel Drug Targets for Inflammatory Bowel Disease Discovered by Scipher Medicine’s Spectra™ Platform
4/28/22
Press releases
Scipher Medicine Publishes New Data Further Supporting Clinical Utility of PrismRA Blood Test
3/29/22
Publications
Budget Impact and Clinical Outcomes of a Molecular Signature to Inform TNFi Treatment Selection in Commercial Patients with Rheumatoid Arthritis
3/16/22
Publications
Network-based response module comprised of gene expression biomarkers predicts response to infliximab at treatment initiation in ulcerative colitis
2/28/22
Press releases
Scipher Medicine to Participate in Truist Securities Life Sciences AI Symposium
2/24/22
Press releases
Scipher Medicine Closes $110 Million Financing
2/11/22
Press releases
Scipher Medicine to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
2/1/22
Press releases
Scipher Medicine Announces Publication of Real-World Study Demonstrating Clinical Utility of PrismRA Blood Test
1/6/22
Press releases
Scipher Medicine Leadership to Present at the 40th Annual J.P. Morgan Healthcare Conference
12/30/21
Publications
Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-ɑ inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis
12/16/21
Press releases
Scipher Medicine Appoints Richard Blackburn to its Advisory Board
Posts navigation
1
2
…
8
Next